?INOEOOO OOEC?AO??? ? IOEUeIIIIEIA?? ?i. O.A. ssIIANUeEIAI AEAAeAI??
IAAeE*IEO IAOE OE?A?IE

AEOIAAIAOeUe ?aaai A?oae?eiae/

OAeE 612.112.94+616.155.32/-053.2:614.876

INIAEEAINO? NOAIIIOEssOe?EIIAI NEEAAeO E?IOIOeEO?A
IA?EOA?E*II? E?IA? Ae?OAE, ssE? I?IAEEAATHOUe IA OA?EOI??ssO ?C
I?AeAEUAIEI ??AIAI ?AAe?IIOEE?Ae?A

14.01.29. — ee?i?/ia ?ioiieia?y

AAOI?AOA?AO

aeena?oaoe?? ia caeiaoooy iaoeiaiai nooiaiy

eaiaeeaeaoa iaaee/ieo iaoe

Ee?a — 1998

Aeena?oaoe??th ? ?oeiien.

?iaioa aeeiiaia a ?inoeooo? iaae?ao???, aeooa?noaa ? a?iaeieia??
AII Oe?a?ie.

IAOEIA? EA??AIEE?:

aeieoi? iaaee/ieo iaoe, i?ioani? *a?ieoia A?eoi? Iaaeiae/,
?inoeooo iaae?ao???, aeooa?noaa ? a?iaeieia?? AII Oe?a?ie,
caa?aeoaa/ eaai?aoi??? ?ioiieia??;

aeieoi? iaaee/ieo iaoe Aioeie?i TH??e Aaiiaae?eiae/, ?inoeooo
iaae?ao???, aeooa?noaa ? a?iaeieia?? AII Oe?a?ie, ea??aiee
a?aeae?eaiiy ee?i?ei-?ioiieia?/ieo ? iaoaaie?/ieo ii?ooaiue o ae?oae.

IO?Oe?EI? IIIIAIOE:

aeieoi? iaaee/ieo iaoe, i?ioani? *oiae Aiaoie?e Aiae??eiae/,
?inoeooo ee?i?/ii? ?aae?ieia?? IOe?I AII Oe?a?ie, caa?aeoaa/ a?aeae?eo
ee?i?/ii? ?ioiieia??;

aeieoi? iaaee/ieo iaoe, i?ioani? Iaeeae?a Aaaeei Ieaen?eiae/,
Oe?a?inueeee iaoeiai-i?aeoe/iee oeaio? aiaeie?eiii? o??o?a?? oa
o?ainieaioieia?? aiaeie?eiieo i?aai?a ? oeaiei IIC Oe?a?ie;
canooiiee aee?aeoi?a.

I?IA?AeIA ONOAIIAA:

Iaoe?iiaeueiee iaaee/iee oi?aa?neoao ?i. I.I. Aiaiiieueoey,
a?aeae?e aenia?eiaioaeueii? oa ee?i?/ii? ?ioiieia??.

Caoeno aeena?oaoe?? a?aeaoaeaoueny «18»_n?/iy_ 1999 ?ieo i 12
aiaeei? ia can?aeaii? niaoe?ae?ciaaii? a/aii? ?aaee Ae 26.552.01 i?e
?inoeooo? ooec?ao??? ? ioeueiiiieia?? ?i. O.A. ssiianueeiai AII
Oe?a?ie (Aae?ana: 252000, i. Ee?a, INI-650, oca?c I?ioan?a ss?, 7).

C aeena?oaoe??th iiaeia iciaeiieoenue o a?ae?ioaoe? ?inoeoooo
ooec?ao??? ? ioeueiiiieia?? ?i. O.A. ssiianueeiai AII Oe?a?ie (i.
Ee?a, oca?c I?ioan?a ss?, 7).

Aaoi?aoa?ao ?ic?neaiee «_7__»_a?oaeiy_ 1998 ?ieo.

A/aiee nae?aoa?

niaoe?ae?ciaaii? a/aii? ?aaee
Aaaioe?aa AE.A.

C A A A E Ue I A O A ? A E O A ? E N O E E A ? I A I O E

AEOOAEUeI?NOUe OAIE. ?aae?iioee?aeia caa?oaeiaiiy aeiae?eey ?
iaei??th c aieiaieo iaaaciae aeey iaeaooi?o iieie?iue (Muhlendahl
K.E., 1995). A oiiaao i?ieiiaiaaiiai ?aae?aoe?eiiai aieeao
iniaeeaiai cia/aiiy iaaoaa? aea/aiiy ii?ooaiue ?ioi?oaoo o ae?oae
(Eoeueyiiaa A.I., 1993). A?aeiii, ui 4 i?eueeiie iaoeaioe?a
eieeoiueiai N?N? caciaee ae?? iaeeo aeic ?aae?iioee?ae?a aiane?aeie
aaa??? ia *AAN (Aa?’yooa? A.A., 1996). O 1986 ?ioe? 1,5 i?eueeiia
aeeoae?a eieeoiueiai N?N? oa aeecueei 160 000 ae?oae, caciaee
cia/iiai ii?ii?iaiiy a?ae ?aae?ieiaeo (Iljin L., 1990; E?ooa?ueia ?.
A., 1996). Aiane?aeie i?aeaeuaii? e?eueeino? Cs-137(134) oa Sr-90 o
a?oio? oa i?iaeoeoao oa?/oaaiiy aeiaeaoeiaiai ii?ii?iaiiy caciathoue
aeeoae? ?aa?ii?a ?aae?aoe?eiiai caa?oaeiaiiy (Aa?’yooa? A.A., 1996).
Caoai?thaai?noue ae?oae, ye? i?iaeeaathoue ia oa?eoi??yo
?aae?aoe?eiiai caa?oaeiaiiy cia/ii c?inea, i?ae aei aaa??? ia *AAN,
aei oiai ae o naia oe??? iiioeyoe?? ae?oae i?aaaeth? iaoieia?y
aeeoaeueii? nenoaie (Noaiaiiaa A.E., 1991; Eoe’yiiaa I.I., 1996).
Cie?aia aeecueei 1/3 a?ae caaaeueii? e?eueeino? ae?oae, ye? caciaee
aieeao ii?ii?iaiiy o ??cieo aeicao oa iino?eii i?iaeeaathoue a
?aa?iiao ?aae?aoe?eiiai eiio?ieth, iathoue cia/i? ooieoe?iiaeuei?
ii?ooaiiy aeeoaeueii? nenoaie (Noaiaiiaa ?. ?., 1996).

Inoaii?ie ai?aeai?ieia?/ieie aeine?aeaeaiiyie aoa aeyaeaiee
aaciina?aaei?e ca’ycie i?ae ?aae?aoe?eiei caa?oaeiaiiyi i?ney aaa???
ia *AAN oa ?eceeii ?aeo ueoiaeaeii? caeice (UC) (Balter M., 1995,
Williams E.D., 1995). Aeia?a a?aeiii, ui e??i ?aeo UC ?ii?coth/a
?aae?aoe?y, cie?aia ?aae?iaeoeai? ?cioiie eiaeo, iiaeooue ni?e/eieoe
?icaeoie oe?ai?aeii? aeenooieoe??, iai?eeeaae a?iioe?ai?aeecio (Becker
D., 1989, Larsen P.R., 1982).

*i?iiaeeuenueea eaoano?ioa cioneea cana?aaeeoe oaaao iaae?ao??a oa
?ioiieia?a ia ??ciiiai?oieo oai?iaeeaeo noaiao, ye? caaaeii iiaeia
iia’ycaoe c ?iceaaeaie ?ioiii? nenoaie (Noaiaiiaa A.E., 1993; *oiae
A.A., 1992; *oiae A.A., 1998). I?ioa, aaciina?aaei?e ca’ycie i?ae
?aae?aoe?eiei ii?ii?iaiiyi ae?oae oa aoaeue-yeeie caoai?thaaiiyie,
ca aeiyoeii ?aeo UC, a oaeiae ci?iaie o ooieoe?iioaaii?
??cieo nenoai aeeoy/iai i?aai?cio, inoaoi/ii ia aeciaiee (O?iiueei
I.Ae., 1996). Oiio iaea?eueo iaa?oioiaaiei ? i?iaaaeaiiy
eiiieaenieo aeine?aeaeaiue noeoiiino? iieaciee?a ?ioiii? oa
a?iio?ci-oe?ai?aeii? nenoai. O?eueee oae? aeine?aeaeaiiy a
aeieia?/ii iani?eyoeeaeo ?aa?iiao e?a?ie aeaaeooue ciiao iaeaaiaeeoe
oe?eani?yiiaaio aeeniaina?ecaoe?th ? icaei?iaeaiiy ae?oae c ii?ooaiiyi
?ioiiiai noaoono. Ianaiia?aae i?iaaaeaiiy ?ioii-aiaeie?eiieia?/iiai
aeine?aeaeaiiy ?c ye?niei aeiciaei noi?iaiaeii iaaeanoue
iiaeeea?noue aea/eoe ?ioiiiaoieia?/i? i?ioeane, ye? coiiaeai?
aaciina?aaei?i aieeaii ?aae?aoe?eiiai ii?ii?iaiiy ia aeeoy/ee
i?aai?ci, oa iaa?oiooaaoe iiaeeeaee eiiieaen ?ioiiei?eaoth/eo
caoiae?a o iaeaooiueiio.

CA’ssCIE ?IAIOE C IAOEIAEIE I?IA?AIAIE, IEAIAIE, OAIAIE.

Aeena?oaoe?eia ?iaioa aeeiiaia a iaaeao Iaoe?iiaeueii? i?ia?aie
iaoeiai-aeine?aeieo ?ia?o uiaei i?i?i?caoe?? iane?aee?a aaa??? ia *AAN
*Ae 19.00.00.7891 N 01.91.00.42252 oa *Ae 01.96 N 01.96. U 016153.

IAOA AeENA?OAOe??. Ia i?aenoaa? ee?i?ei-?ioiieia?/iiai
aeine?aeaeaiiy ae?oae, ye? i?iaeeaathoue ia caa?oaeiaieo
?aae?iioee?aeaie oa?eoi??yo, aeyaeoe iiaeeeaee aeicicaeaaeiee aieea
?aae?aoe?eiiai ii?ii?iaiiy ia ?ioiio nenoaio, ai?no e?ioioeeoa?ieo
noaiiioeyoe?e ia?eoa?e/ii? e?ia?, a oaeiae ?ieue ie?aieo
e?ioioeeoa?ieo noaiiioeyoe?e uiaei iiaeeeaeo ci?i
ooieoe?iioaaiiy a?iio?ci-oe?ai?aeii? nenoaie.

CAAAeAIIss AeINE?AeAEAIIss:

1. I?iaanoe aeine?aeaeaiiy ??ai?a aieiaieo e?ioioeeoa?ieo
noaiiioeyoe?e ia?eoa?e/ii? e?ia? ae?oae, ui /anoi oai??thoue ia
?ani??aoi?i? caoai?thaaiiy (?? a?oia caei?ia’y) oa caei?iaeo ae?oae,
ye? i?iaeeaathoue o naeao, aea ianaeaiiy io?eiaei caaaeueia ?aae?aoe?eia
ii?ii?iaiiy a?ae Cs-137(134) oa Sr-90 ??ciiai nooiaiy;

2. Aeaoe oa?aeoa?enoeeo e?ioioeeoa?ieo noaiiioeyoe?e
ia?eoa?e/ii? e?ia? ae?oae ?c ??cieie ?iaeea?aeoaeueieie aeicaie
ii?ii?iaiiy UC a?ae ?aae?iaeoeaiiai eiaeo, ye? iino?eii i?iaeeaathoue
ia oa?eoi??yo ?aae?aoe?eiiai caa?oaeiaiiy;

3. I?iaanoe aeine?aeaeaiiy ooieoe?? a?iio?ci-oe?ai?aeii? nenoaie,
??ai?a aooiaioeo?e aei UC, a oaeiae oeueo?aniiia?ao?/ia aeine?aeaeaiiy
UC ae?oae ?c ??cieie aeicaie ii?ii?iaiiy UC a?ae I-131;

4. Aea/eoe o? ae nai? iieacieee o ae?oae, ui /anoi oai??thoue ia
?ani??aoi?i? caoai?thaaiiy (II a?oia caei?ia’y) oa caei?iaeo ae?oae,
ye? i?iaeeaathoue o naeao ia oa?eoi??yo, ui ia caciaee ?aae?aoe?eiiai
caa?oaeiaiiy aiane?aeie aaa??? ia *AAN.

IAOEIAA IIAECIA ?IAIOE. Aia?oa ca aeiiiiiaith no/anieo iaoiae?a
aeine?aeaeaiiy ?ioiii? nenoaie oa ye?niiai aeiciaiai noi?iaiaeo aoei
i?iaaaeaia aaaaoi??/ia aeine?aeaeaiiy iniaeeainoae ?ioi?oaoo oa noaio
a?iio?ci-oe?ai?aeii? nenoaie aeeoeie i?ae aieeaii ??cieo aeic
?aae?iioee?ae?a. Aia?oa iieacaii oaeiae ui:

1) cieaeaiiy a?aenioeo CD3+CD4+ T-ee?oei oaeia??a/?iaeoeoi??a
ni?aiaaea? ?c i?aeaeuaiiyi ??ai?a caaaeueiiai ii?ii?iaiiy
?aae?iioee?aeaie *i?iiaeeuenueeeo aeeeae?a o ae?aiacii? iaeeo aeic eeoa
o ae?oae, ye? /anoi oai??thoue ia ?ani??aoi?i? ?ioaeoe??. I?e oeueiio,
ianaiia?aae o oe?e a?oi? cia/ii ca?eueoaia e?euee?noue ae?oae ?c
iecueeei a?aenioeiaei ??aiai CD3+ T-ee?oei, aenieei a?aenioeiaei
??aiai CD16+ aai CD3-/CD16+,56+ ee?oei — i?e?iaeieo e?ea??a (IE) oa
aeiaaeeaie iie?e?ioaaeaiiiao??, ui iiaea aeacoaaoe ia ?icaeoie
caaaeueiiai aeecaaeaioaoe?eiiai neiae?iio;

2) o ae?oae, ye? caciaee aino?iai ii?ii?iaiiy UC, ?nio?
aeicicaeaaeia i?aeaeuaiiy ye a?aenioeiaiai ??aiy CD3+CD4+ T-ee?oei
oaeia??a/?iaeoeoi??a, oae ? CD3+CD4+/CD3+CD8+ ee?oeiiiai
ni?aa?aeiioaiiy, a oaeiae I-131 aeicicaeaaeia cieaeaiiy ye a?aenioeiaeo
??ai?a, oae ? aaniethoiiai ai?noo CD3+CD8+ T-ee?oei;

3) ?nio? iiceoeaia caeaaei?noue CD5+ B-Eo a?ae ??ai?a aioeo?e aei
i?e?iniiaeueiiai aioeaaio UC o ae?oae, ye? caciaee ii?ii?iaiiy UC a?ae
?aae?i?cioii?a eiaeo, ui i?aeoaa?aeaeo? aooi?ioiio i?e?iaeo
oe?ai?aeii? iaoieia??;

4) o ae?oae, ye? caciaee aieeao ii?ii?iaiiy UC a?ae
?aae?i?cioii?a eiaeo, cia/ii ca?eueoaia e?euee?noue na?iiiceoeaieo ca
oe?ai?aeieie aioeo?eaie in?a oa ??ai? oeeo aioeo?e iiceoeaii
ei?aeththoue ?c aeicaie I-131 ia UC;

5) o ae?oae, ye? caciaee aino?iai ii?ii?iaiiy UC, ?nio?
aeicicaeaaeia oaiaeaioe?y aei cieaeaiiy ??aiy a?eueiiai oe?ieneio, yea
na?ae/eoue i?i i?aeaeuaiiy ?eceeo ?icaeoeo a?iioe?ai?aeecio o oeeo
ae?oae;

6) iayai?noue cia/ieo ii?ooaiue aoino?oeoo?e UC o aeaeyae?
a?ia?aoiu?eueiino? ?c ae?eyieaie o?a?ico oa a?iiaoiu?eueiino?, o
ae?oae, ye? caciaee ii?ii?iaiiy UC a?ae I-131 o ??cieo aeicao,
ni?aiaaea? c oee?eoeyoe??th a e?ia? aooiaioeo?e aei UC.

I?AEOE*IA CIA*AIIss IAeA?AEAIEO ?ACOEUeOAO?A.

1. ?aeiiaiaeiaaii aeey iii?oi?eiao noaio caei?ia’y o ae?oae, ye?
caciaee ?aae?aoe?eiiai aieeao, ?ioiieia?/i? aeine?aeaeaiiy ?c
aea/aiiyi e?ioioeeoa?ieo noaiiioeyoe?e ia?eoa?e/ii? e?ia? c
/anoioith 1 ?ac ia ??e. Aiaeii/an ae?oe, o yeeo aeyaeai? iaoieia?/i?
ci?ie aoino?oeoo?e UC, iio?eaothoue aea?/? ia ??e oeueo?acaoeiaiai
aeine?aeaeaiiy UC, ianoaaeaiiy ooieoe?? a?iio?ci-oe?ai?aeii? nenoaie ?
iiaeeaeaiiai ?ioiieia?/iiai ianoaaeaiiy.

2. Iaa?oioiaaii ? i?aaenoaaeaii eaai?aoi?i? e??oa??? ioe?iee
ae?aaeaiiino? ?ioiieo ? aooi?ioiieo ii?ooaiue o ae?oae, ye? caciaee
?aae?aoe?eiiai iaaaioaaeaiiy. Ieie iiaeooue aooe ai?no CD3+CD4+ ee?oei
oa ??aaiue CD3+CD4+/CD3+CD8+ ee?oeiiiai ni?aa?aeiioaiiy.

I?aeoe/i? iieiaeaiiy aeena?oaoe?eii? ?iaioe a?aeia?aaeaeai? oaeiae
a iin?aieeo «Iniaeeaino? ia?aa?ao aaa?oiino?, ?iae?a, noaio
iiaiia?iaeaeaieo oa i?iya?a niiaoe/ii? ineoiiaa?ieia?/ii? iaoieia?? o
ae?oae, ye? caciaee ?aae?aoe?eiiai aieeao aiane?aeie *i?iiaeeuenei?
eaoano?ioe» (Ee?a, 1997).

INIAENOEE AIANIE CAeIAOAA*A. Ca?? iniiaiiai iaoa??aeo
i?ioyaii aeine?aeaeaiiy, inai?iiy iaoiae?a, i?iaaaeaiiy
aeine?aeaeaiue, aecia/aiiy iieaciee?a oa noaoenoe/ia ia?iaea
?acoeueoao?a cae?eniai? caeiaoaa/ai iniaenoi; ocaaaeueiaii io?eiai?
?acoeueoaoe oa noi?ioeueiaaii aeniiaee ? i?aeoe/i? ?aeiiaiaeaoe??.

AI?IAAOe?ss ?ACOEUeOAO?A AeENA?OAOe??. Io?eiai? ?acoeueoaoe
aeine?aeaeaiue ii?eethaeiaii ia: 9-io I?aeia?iaeiiio
?ioiieia?/iiio Eia?an? o Nai-O?aioeenei, NOA (23-29 eeiiy 1995 ?ieo);
I?aeia?iaei?e Eioa?aioe?? «One decade after Chernobyl: Summing
up the consequences of the accident», A?aeaiue, Aano??y (8-12 o?aaiy,
1996 ?ieo); Iaoeiai-i?aeoe/i?e eiioa?aioe?? «A?aeaeaeai?
iane?aeee ii?ii?iaiiy a ?ioii?e oa aaiiiiaoe/i?e nenoaiao», Ee?a,
Oe?a?ia (7-10 aeiaoiy 1996 ?ieo).

IOAE?EAOe??. Ca iaoa??aeaie aeena?oaoe?? iioae?eiaaii 12
iaoeiaeo ?ia?o.

NO?OEOO?A ? IANssA AeENA?OAOe??. Aeena?oaoe?y aeeeaaeaia ia 152
noi??ieao, ?ethno?iaaia 20 oaaeeoeyie oa 15 ?enoieaie ?
neeaaea?oueny c anooio, iaeyaeo e?oa?aoo?e, iieno iaoa??ae?a ?
iaoiae?a aeine?aeaeaiiy, 2 ?icae?e?a aeanieo aeine?aeaeaiue,
iaaiai?aiiy ?acoeueoao?a, aeniiae?a ? i?aeoe/ieo ?aeiiaiaeaoe?e.
A?ae?ia?ao?/iee iieaae/ee i?noeoue 271 aeaea?aei, c ieo 129 — ?iicaiieo
aaoi??a.

I N I I A I E E C I ? N O ? I A I O E

IAOA??AEE ? IAOIAeE AeINE?AeAEAIIss. Aeine?aeaeaiiy aoaeo?a
?aae?iaeoeaiiai ii?ii?iaiiy aiane?aeie aaa??? ia *AAN 1986 ?ieo
aeeiioaaeinue c 1991 ii 1997 ??e. ?ioiieia?/ia ianoaaeaiiy aoei
i?iaaaeaii o 311 ae?oae oa i?aee?oe?a a?eii a?ae 6 aei 17 ?ie?a, ye?
iino?eii i?iaeeaaee o 15 ?aae?aoe?eii-caa?oaeiaiieo naeeuao
*a?i?a?anueei? oa Ee?anueei? iaeanoae oa 178 ae?oae a?eii a?ae 6 aei
14 ?ie?a, ye? i?iaeeaaee ia ia caa?oaeiaieo ?aae?iioee?aeaie
oa?eoi??yo Iieoaanueei? iaeano?. Ona aeine?aeaeaiiy oiiaii iiaeia
iiae?eeoe ia 2 aoaie. Ia ia?oiio aoai? (1991-1994 ??.) aea/aee aieea
iaeeo aeic ii?ii?iaiiy a?ae Cs-137(134)oa Sr-90 ia ?ioiio nenoaio
ae?oae. Ia ae?oaiio aoai? (1993-1997 ??.) aea/aee iniaeeaino?
?ioi?oaoo oa noai a?iio?ci-oe?ai?aeii? nenoaie o ae?oae ?c ??cieie
aeicaie ii?ii?iaiiy UC a?ae I-131.

Ia ia?oiio aoai? iniiaio a?oio neeaee 205 ae?oae a?eii a?ae 6 aei
14 ?ie?a, ye? iino?eii iaoeathoue ia oa?eoi??yo ?aae?aoe?eiiai
caa?oaeiaiiy. Ia i?aenoaa? aiae?co iniaenoeo iaaee/ieo ea?oie,
iaaee/iiai aiaiiaco, ee?i?/iiai niinoa?aaeaiiy i?ioyaii 1991-1994 ??.
oa caaaeueiiaeciaieo e?eoa???a (Loda F.A., 1972; Monto A.S., 1976) aiie
aoee iiae?eai? ia 2 a?oie, a naia: ae?oe, ye? /anoi oai??thoue ia
?ani??aoi?i? caoai?thaaiiy (Ae*O) oa caei?ia? ae?oe. Ae*O, ui i?iaeeaaee
iiaeeco *AAN, iaee 4 ? a?eueoa aeiaaee?a caoai?thaaiue ?ani??aoi?iiai
o?aeoo (ea?eiaio?aoa?o, a?iio?o, iiaaiii?y) ia ??e oa iaeaaeaee aei II
a?oie caei?ia’y. Ae?oe, ye? iaee o?ii?/io iaoieia?th
?ani??aoi?ieo oeyo?a oa ii?oieia?/i? ci?ie o eaaaiyo, ae?oe c
aea?a?/iei eiiiiiaioii aai III-IV a?oi caei?ia’y ia ianoaaeoaaeeny
? ia aoee aeeth/ai? o aeine?aeaeaiiy. O 1991-92 ??. ?ioiieia?/ia
aeine?aeaeaiiy aoei aeeiiaia na?aae 45 Ae*O oa 40 caei?iaeo
ae?oae iniiaii? a?oie. O 1993-94 ??. ?ioiieia?/ia aeine?aeaeaiiy
aoei aeeiiaii na?aae ?ioeo 71 Ae*O oa 49 caei?iaeo ae?oae iniiaii?
a?oie. A?oiith ii??aiyiiy oeueiai ?ioiieia?/iiai aeine?aeaeaiiy
aoee 148 ae?oae a?eii a?ae 6 aei 14 ?ie?a, ye? i?iaeeaaee o n?euenuee?e
i?noeaaino? Iieoaanueei? iaeano?. Ia i?aenoaa? oeo naieo iaoiae?a oa
e?eoa???a oe? ae?oe aoee oaeiae iiae?eai? ia Ae*O, ye? iaee ?? a?oio
caei?ia’y oa caei?iaeo ae?oae. O 1991-92 ??. Aeine?aeaeaiiy ai?noo
e?ioioeeoa?ieo noaiiioeyoe?e ia?eoa?e/ii? e?ia? aoei aeeiiaii
na?aae 25 Ae*O oa 36 caei?iaeo ae?oae a?oie ii??aiyiiy. O 1993-94 ??.
?ioiieia?/ia ianoaaeaiiy aoei i?iaaaeaii na?aae ?ioeo 42 Ae*O oa 45
caei?iaeo ae?oae a?oie ii??aiyiiy.

I?ae /an ee?i?ei-?ioiieia?/iiai ianoaaeaiiy an? ae?oe a?aea?aeoaaee
oeieo, ia iaee i?aeaeuaii? oaiia?aoo?e oa eaoeth oa ia io?eioaaee
e?eoaaiiy aoaeue-yeeie ?ioiinoi?aneaieie aai noa?i?aeieie i?aia?aoaie.
I?ioyaii o?ueio ?ie?a (1991-1993) na?aaeiy noia?ia aoaeoeaia
aea?aaeaioia aeica (NNAAAe) aioo??oiueiai ? ciai?oiueiai ii?ii?iaiiy
a?ae Ns-137(134) oa Sr-90 aeey ianaeaiiy, yea i?iaeeaaei a ianaeaieo
ioieoao aoea ioe?iaia IIC Oe?a?ie (oiaoi ia aoea
?iaeea?aeoaeueiith) ? ciaoiaeeeanue a iaaeao 0,57-7,6 iCa. Ca?aeii
c ii?iaie ?aae?aoe?eii? aaciaee Oe?a?ie (I?AO-97), ae?oe aoee iiae?eai?
ia aea? a?oie c NNAAAe < 1,0 iCa ? > 1,0 iCa.

Ia ae?oaiio aoai? ianoaaeaii 106 ae?oae oa i?aee?oe?a a?eii a?ae 7
aei 17 ?ie?a. Eiioeiaaioe aoee a?ae?a?ai? ia i?aenoaa? aiae?co
iniaenoeo iaaee/ieo ea?oie, iaaee/iiai aiaiiaco, ee?i?/iiai
ianoaaeaiiy, aea aac ciaiiy eaai?aoi?ieo oa oeueo?aniiia?ao?/ieo
aeaieo UC. An? aiie ia iaee a aiaiiac? aoaeue-yeeo o?ii?/ieo
caoai?thaaiue oa i?ae /an ianoaaeaiiy aoee caei?ia?. Ia i?aenoaa?
?iaeea?aeoaeueieo iiaeeiaieo aeic (?IAe) ia UC a?ae ?-131 (?IAe
iaaeai? a?aeae?eii aeiceiao??? oa ?aae?aoe?eii? a?a??ie IOe?I AII
Oe?a?ie) ae?oe oa i?aee?oee aoee iiae?eai? ia 3 a?oie. O I a?oi? aeice
ia UC a?ae I aoee < 1,0 A? (n=49); o II - 1,0-2,0 A? (n=38); o III - iiiaae 2,0 A? (n=19). I?e oeueiio NNAAAe Cs-137(134) oa Sr-90 aeey eiaeii? c oeeo a?oi ia a?ae??ciyeany iaeia a?ae iaeii?. A?oiith ii??aiyiiy oeueiai aeine?aeaeaiiy aoee 75 caei?iaeo ae?oae a?eii a?ae 6 aei 14 ?ie?a, ye? i?iaeeaaee o n?euenuee?e i?noeaaino? Iieoaanueei? iaeano?. Aeey aea/aiiy ai?noo e?ioioeeoa?ieo noaiiioeyoe?e ia?eoa?e/ii? e?ia? canoiniaoaaee aeaieieuei?iao i?ioi/io oeeoiiao??th c aeei?enoaiiyi iiiieeiiaeueieo aioeo?e (IEA). Aeey i?/aiiy e?ioioeeoa?ieo noaiiioeyoe?e o 1991-92 ??. Aeei?enoiaoaaee iaeiieieuei?ia? IEA, a c 1993 ?ieo - aeaieieuei?ia? IEA a?ae Becton Dickinson Immunocytometry Systems (BDIS, Erembodegem, Aaeuea?y). Aiae?c e?ioioeeoa?ieo noaiiioeyoe?e i?iaiaeeee ia oeeoiiao?? FACScan ?c aeei?enoaiiyi eiii'thoa?ieo i?ia?ai SimulSET ? FACSCAN (BDIS). Ne?iaaoeia? eiioeaio?aoe?? caaaeueiiai oe?ieneio (O4), a?eueiiai O4, oe?aio?iiiiai ai?iiio (OOA), a oaeiae e?euee?niee ??aaiue oe?aiaeiaoe?iiaeo aioeo?e (OAA) oa aioeo?e aei oe?ai?aeiiai i?e?iniiaeueiiai aioeaaio (OIA) aecia/aee ?ioiioa?iaioiei iaoiaeii ca aeiiiiiaith eiia?oe?eieo iaai??a (Cobas Core, Basel, Oaaeoea??y ? International Immune-Diagnostics, Nevada, NOA) oa ae?aaiinoe/iiai iaeaaeiaiiy o??ie Hoffmann-La Roch (Oaaeoea??y) ? Labsystems (O?ieyiae?y). Oeueo?aniiia?ao?/i? aeine?aeaeaiiy UC aoee aeeiiai? ca aeiiiiiaith iaeaaeiaiiy Aloka SSD 500 (Aloka Co. LTD., ssiii?y) c aeei?enoaiiyi 7.5-MHz o?ainaeoeoi?a na?aae 94 ae?oae c ??cieie aeicaie ii?ii?iaiiy UC a?ae I-131, a oaeiae na?aae 60 ae?oae a?oie ii??aiyiiy. Ia?iaeo io?eiaieo aeaieo i?iaiaeeee ca aeiiiiiaith eiii'thoa?iiai iaeaoo i?ia?ai "Statgrafics-V. 2.6." aeey IBM PC. Noaoenoe/io a??ia?aeio a?aei?ii?noue i?ae a?oiaie oaeiae aiae?coaaee ca aeiiiiiaith iaoiaeo X2. ?ACOEUeOAOE AeINE?AeAEAIUe ? ?O IAAIAI?AIIss. Aiae?c aeaieo ia?oiai aoaio ?ioiieia?/iiai aeine?aeaeaiiy na?ae/eoue i?i oa, ui na?aae Ae*O iniiaii? a?oie e?euee?noue ae?oae ?c cia/ii cieaeaiei (I - 2SD a?ae caei?iaeo ae?oae a?oie ii??aiyiiy) ??aiai CD3+ O-ee?oei aoea a??ia?aeii a?eueoith 20/116 (17,2%), i?ae na?aae Ae*O a?oie ii??aiyiiy 1/67 (1,5%), (P < 0,001). E??i oiai, i?ioyaii aeine?aeaeaiiy aeey an?o Ae*O iniiaii? a?oie oa?aeoa?iei aoa a??ia?aeii cieaeaiee a?aenioeiaee ai?no CD3+ T-Eo ?, iaaiaee, a??ia?aeii i?aeaeuaiee a?aenioeiaee ai?no i?e?iaeieo e?ea??a ii a?aeiioaiith aei Ae*O a?oie ii??aiyiiy. Aeoaea aaaeeeaei ? oaeiae oa, ui o 1991-92 ??. a?aenioeiaee ai?no CD4+ ee?oei oaeia??a/?iaeoeoi??a na?aae on?o Ae*O iniiaii? a?oie ia a?ae??ciyany a?ae Ae*O a?oie ii??aiyiiy (P=0,06). Aiaeii/an aiae?c a?aenioeiaeo ??ai?a CD3+CD4+ T-ee?oei ee?oei oaeia??a/?iaeoeoi??a o 1993-94 ??. na?aae on?o Ae*O iniiaii? a?oie aeyaea a??ia?aeia cieaeaiiy ai?noo oeeo ee?oei, uiaei Ae*O a?oie ii??aiyiiy (32,3+0,6%, ae?aiacii cia/aiue 14-44% i?ioe 35,6+0,9%, ae?aiacii cia/aiue 24-53%, a?aeiia?aeii; P<0,009). ?ai?oa aaaaoueia aaoi?aie aoei iieacaia cieaeaiiy a?aenioeiaiai ai?noo O-Eo na?aae e?ea?aeaoi??a aaa??? ia *AAN (*oiae A.A., Aaceea Ae.A., 1992 oa 1996; Eiienna?aiei N.A., Cae E.I., 1994). Aiaeii/an aia?oa aoei iieacaii, ui cieaeaiiy a?aenioeiaiai ??aiy O-ee?oei na?aae Ae*O, ye? ciaoiaeyoueny i?ae aieeaii o?eaaeiai ii?ii?iaiiy o iaeeo aeicao, ? iane?aeeii a??ia?aeiiai iaae?iiy ??ai?a noaiiioeyoe?? CD3+CD4+ T-ee?oei (oaae. 1). Oae? aeai? aeacothoue ia oa, ui i?iaeeaaiiy ia oa?eoi??yo ?aae?aoe?eiiai eiio?ieth aieeaa? ia ??ai? e?ioioeeoa?ieo noaiiioeyoe?e o Ae*O. I?ae caei?iaeie ae?oueie iniiaii? oa eiio?ieueii? a?oi ia aoei a??ia?aeieo a?aei?iiinoae o a?aenioeiaeo ??aiyo aieiaieo e?ioioeeoa?ieo noaiiioeyoe?e. Aiaeii/an, ia a?aei?io a?ae a?oie ii??aiyiiy, iacaeaaeii a?ae NNAAAe niinoa??aa?oueny a??ia?aeia ??cieoey i?ae ??aiyie CD3+ O-ee?oei oa CD3+CD4+ ee?oei o caei?iaeo ? Ae*O. I?e oeueiio c?inoaiiy NNAAAe na?aae Ae*O noi?iaiaeaeoaaeiny cieaeaiiyi ??ai?a ye T-ee?oei oaeia??a/?iaeoeoi??a, oae ? CD3+CD4+/CD3+CD8+ ee?oeiiiai ni?aa?aeiioaiiy. ??ai? CD3+CD8+ T-, CD19+ A-Eo oa CD3-/CD16,CD56+ IE ia iaee a??ia?aeieo a?aei?iiinoae i?ae aeine?aeieie a?oiaie oa a?oiaie ii??aiyiiy. Aiaeii/an aiae?c aeaieo aaniethoii? e?eueeino? ee?oei ??cieo e?ioioeeoa?ieo noaiiioeyoe?e aeyaea a??ia?aeia i?aeaeuaiiy ??aiy eeoa IE o Ae*O ?c NNAAAe Cs-137(134) i Sr-90 > 1,0 iCa o ii??aiyii? ?c Ae*O eiio?ieth (0,52 + 0,05 x 10 /L
i?ioe 0,33 + 0,03 x 10 /L, a?aeiia?aeii; P<0,02). ?ioiieia?/i? ci?ie o Ae*O noi?iaiaeaeoaaeenue iaaieie ee?i?/ieie neiioiiaie. Oaaeeoey 1. A?aenioeiaee ai?no aieiaieo e?ioioeeoa?ieo noaiiioeyoe?e ia?eoa?e/ii? e?ia? ae?oae, ye? aoee ianoaaeai? o 1993-1994 ??., (M+m). E?ioioeeoa?i? noaiiiiioeyoe?? Ae?oe a?oie ii??aiyiiy Ae?oe ?c NNAAAe ca 1991-93 ??. ca iiaa?oiaaee < 1,0 iCa > 1,0 iCa

aioeaaiaie Caei?ia? (n=45) Ae*O (n=42) Caei?ia? (n=17) Ae*O (n=34)
Caei?ia? (n=32) Ae*O (n=37)

CD3+ T-ee?oeie 66,9+0,8 66,9+0,9 68,1+,3 63,3+1,2*, # 66,4+1,3
63,5+0,9*

CD3+CD4+ ee?oeie 35,7+0,7 35,6+0,9 37,1+1,6 33,3+0,8# 36,2+1,3
31,3+0,9@, &

CD3+CD8+ ee?oeie 25,4+0,8 25,8+0,8 24,0+1,1 24,4+0,8 24,3+1,0 26,6+0,9

CD3+CD4+/ CD3+CD8+ ni?aa?aeiioaiiy 1,5+0,1 1,5+0,1 1,6+0,1 1,4+0,05
1,6+0,1 1,3+0,07**

CD19+ B-ee?oeie 15,8+0,7 16,0+0,7 15,4+0,9 16,9+0,6 14,1+0,8 16,3+0,8

CD3-/CD16+,56+ IE 11,4+0,7 11,3+0,7 10,5+1,2 13,5+1,2 12,8+1,1 13,9+1,0

I?ei?oee:

1.* — P<0,05 o ii??aiyii? ?c Ae*O eiio?ieth; 2.@ - P<0,005 o ii??aiyii? ?c Ae*O eiio?ieth; 3.# - P<0,05 o ii??aiyii? c caei?iaeie ?c NNAAAe < 1,0 iCa; 4.& - P<0,05 o ii??aiyii? c caei?iaeie ?c NNAAAe > 1,0 iCa;

5.** — P<0,005 o ii??aiyii? c caei?iaeie ?c NNAAAe > 1,0 iCa.

?en. 1. na?ae/eoue i?i a??ia?aeia c?inoaiiy, o ii??aiyii? ?c Ae*O
eiio?ieth, e?eueeino? aeiaaee?a ca?eueoaiiy i?aeiaa?iieo
ie?aeaeei ?/aai aaeaii?aeieo aaaaoaoe?e, a oaeiae ca?eueoaiiy
?ici??o aeayeeo a?oi ia?eoa?e/ieo

?en. 1. A?aenioie Ae*O ?c e?ioaaeaiiiao??th oa ??ciith NNAAAe
Cs-137(134) ? Sr-90 ca ?ieaie aeine?aeaeaiiy

e?ioaoe/ieo aoce?a na?aae Ae*O iniiaii? a?oie (P<0,01). A?eueo oiai, o 1993-1994 ??. na?aae Ae*O, ye? iaee NNAAAe Cs-137(134) i Sr-90 > 1,0 iCa, a?aenioie ae?oae c oaeith ?aaeoe??th ia?eoa?e/ii?
e?ioaoe/ii? nenoaie aoa a??ia?aeii aeuei, i?ae na?aae Ae*O c NNAAAe < 1,0 iCa (P<0,05), oiaoi e?euee?noue aeiaaee?a c?inoaea ye ?c i?aeaeuaiiyi NNAAAe, oae ? c /anii i?ney aaa??? ia *AAN. Oaeei /eiii, iaaaaeai? aeai? c aaeeeith a??ia?aei?noth aeacothoue ia oa, ui aeyaeaia ??cieoey a ??aiyo e?ioioeeoa?ieo noaiiioeyoe?e na?aae Ae*O iniiaii? a?oie ? ?acoeueoaoii ?aae?aoe?eiiai aieeao, a ia ?ioeo oaeoi??a, oaeeo iai?eeeaae, ye ?ani??aoi?i? ?ioaeoe??. C ?ioiai aieo, iiaeeeai, ui aaaaoi?aciaee aieea iaoiaaiieo aai aioeaaiieo noeioe?a ? iaiao?aeiei aeey ?icaeoeo ?aae?aoe?eii-?iaeoeiaaieo ?ioiieo ii?ooaiue. E??i oiai, ?ioiia nenoaia aeayeeo ae?oae, ye? iathoue i?e?iaeaeaio noeeuei?noue aei iiaoi?ieo caoai?thaaiue aeeoaeueieo oeyo?a, a oaeiae iioeiaeaeaiio ?ioiio a?aeiia?aeue, iiaeooue aooe iniaeeai /ooeeaeie aei ii?ii?iaiiy. Inoaiith aeoieo i?aeoaa?aeaeo? oa, ui a?aeiinii aeniea e?euee?noue Ae*O, ye? i?iaeeaathoue ia eiioai?iiaaieo ?aae?iioee?aeaie oa?eoi??yo, iathoue aeoaea iecuee? ??ai? CD3+ Eo, aea, aiaeii/an, na?aae Ae*O a?oie aeine?aeaeaiiy aoee oaeiae ae?oe c aenieei ??aiai oeeo ee?oei. Oe?eeii ?iia??ii, ui ?iaeea?aeoaeuei? oaeoi?e, aeeth/ii aaiaoe/i?, iiaeooue coiiaethaaoe /ooeea?noue ??ciiai nooiaiy aei ii?ii?iaiiy na?aae ?ioiieiiiaoaioieo ee?oei. ?ai?oa aoei iieacaii, ui Ae*O iathoue aaiaoe/io noeeuei?noue aei cieaeaiiy ??aiy CD4+ ee?oei ? CD4+/CD8+ ni?aa?aeiioaiiy oa ui ?aae?i/ooeea?noue ?ioiieiiiaoaioieo ee?oei in vivo ?aaoeth?oueny aaiaoe/ieie oaeoi?aie (Eaeeieia I.I., 1995; Sado T., 1985). E??i oiai, iecuee? aeice ii?ii?iaiiy ia aieeaathoue ia oaaioeeoic, aea ii?ooothoue i?ioean iiaeaaaiiy aioeaaio ?ioiieiiiaoaioiei ee?oeiai (Sandberg E.T., 1996). Oiio cieaeaiiy ??ai?a CD3+ O- oa CD3+CD4+ T-ee?oei oaeia??a/?iaeoeoi??a iiaea aooe aaaeeeaei o iineaaeai? ee?oeiiiiaoiiaeaii? ?ioiii? a?aeiia?ae? o Ae*O. I?ioa a?aeiii, ui aeayea cieaeaiiy ??aiy CD3+ ee?oei ia ? niaoeeo?/iei aeey caoai?thaaiue aeeoaeueii? nenoaie (*a?iooaiei A.O., 1998). Oe?eeii iiaeeeai, ui cieaeaiiy ??ai?a CD3+, CD3+CD4+ T-ee?oei oaeia??a/?iaeoeoi??a oa aeyaeaia ?aaeoe?y e?ioi?aeii? oeaieie o Ae*O ? iciaeaie caaaeueiiai aeecaaeaioaoe?eiiai neiae?iio (Eiaaeaa A.E., 1990; Noaiaiiaa ?.!., 1996; Podpalov V.P., 1996), yeee oi?io?oueny i?ae aieeaii iaeeo aeic ?aae?aoe?? ia ?ioiio nenoaio aeeoeie. Oeth aeoieo i?aeoaa?aeaeo? oaeiae oa, ui aino?? ?ani??aoi?i? caoai?thaaiiy (A?C) o Ae*O iniiaii? a?oie a?ae??ciyeeny caoyaeiei ia?aa?aii, o?eaaeith a?ia?oa?i??th aai noaoaa?ee?oaoii, a?aeiinii /anoeie a?o?aea?/iei, noaeiiiei, a oaeiae aaaeii?iaeueiei neiae?iiaie, o ii??aiyii? c a?oiith eiio?ieth. I?eaeecii eiaeia i'yoa Ae*O ?c iniiaii? a?oie oai??ea ia A?C oa/aai oiicee?o, aaeaii?aeeo, ioeo /ano?oa 7 ?ac?a ia ??e i?ioe 8,1% o Ae*O a?oie ii??aiyiiy. C ?ioiai aieo, oe?eeii ?iia??ii, ui o?eaaea ii?ii?ithaaiiy iaeeie aeicaie ?aae?iioee?ae?a iiaea ii?oooaaoe ??no, aeic??aaiiy oa aeeoa?aioe?aoe?th, ye noiaao?iaeo ee?oei /a?aiiiai e?noeiaiai iiceo, oae ? iiia?aaeiee?a ie?aieo Eo noaiiioeyoe?e, iai?eeeaae CD4+ ee?oei o ae?oae, ye? iino?eii i?iaeeaathoue ia oa?eoi??yo ?aae?aoe?eiiai caa?oaeiaiiy. Oe?eeii iiaeeeai, ui ?aae?i?iaeoeiaai? oeueo?ano?oeoo?i? ii?ooaiiy ee?oeiieo yaea? iiaeooue ni?eyoe i?aeaeuaiiiio ??aith aiiioico Eo (ss?eeei A.A., 1988). Aiae?c aeaieo ae?oaiai aoaio ?ioii-aiaeie?eiieia?/iiai aeine?aeaeaiiy ae?oae, ye? iaee ??ci? aeice ii?ii?iaiiy UC a?ae I-131,aeaco? ia oa, ui ne?iaaoeiaee ??aaiue OOA o oeeo ae?oae aoa a??ia?aeii i?aeaeuaiee uiaei a?oie ii??aiyiiy. Aiaeii/an oea ca?eueoaiiy ??aiy OOA ia caeaaeaei a?ae aeice ii?ii?iaiiy UC (r=0,003; P>0,05). C ?ioiai aieo, o a?oi? ae?oae ?c aeicaie ii?ii?iaiiy iiiaae
2,0 A? ??aaiue a?eueiiai O4 aoa a??ia?aeii ieae/ei, i?ae o a?oi?
ii??aiyiiy (11,3 + 0,6 ieiie/e i?ioe 13,5 + 0,4 ieiie/e, a?aeiia?aeii;
P<0,005). A?eueo oiai, aiae?c iieacaa iayai?noue a??ia?aeii? ei?aeyoe?eii? caeaaeiino? i?ae ??aiyie a?eueiiai O4 oa aeicaie ii?ii?iaiiy UC a?ae ?aae?ieiaeo (r= -0,174; P<0,027). Eeoa o 14% ae?oae a?oie ii??aiyiiy oa o iiiaae 50% ae?oae, ye? caciaee ii?ii?iaiiy UC a?ae I-131, aeyaeee iayai?noue ne?iaaoeiao OAA (P < 0,001). E??i oiai, oee?eoethth/? ne?iaaoeia? TMA aeyaeyeeny i?eaeecii o 5 ?ac?a /ano?oa na?aae ae?oae, ye? iaee ii?ii?iaiiy UC a?ae ?aae?ieiaeo, i?ae o ae?oae a?oie ii??aiyiiy (17% i?ioe 3%, a?aeiia?aeii; P<0,005). Ca aeaieie oeueo?aniiia?ao?/iiai aeine?aeaeaiiy UC 17,0% ae?oae ?c aeicaie I-131 ia UC iaee cia. Aiaeii/an i?ioyaii aeine?aeaeaiiy ia aoei aeyaeaii aeiaeiiai aeiaaeeo ciao na?aae ae?oae oa i?aee?oe?a a?oie ii??aiyiiy. E??i oiai, oaeiae 17,0% ae?oae ?c aeicaie I-131 ia UC iaee i?aeaeuaiiy aoiu?eueiino? ?/aai ae?eyiee o?a?ico UC (o a?oi? ii??aiyiiy - aeiaeiiai aeiaaeeo). Oaeei /eiii, ia a?aei?io a?ae a?oie ii??aiyiiy (3,3%), cia/i? oeueo?aniiia?ao?/i? ci?ie ?ici??o (cia) ?/aai aoiu?eueiino? UC, a naia: cia/ia a?ia?- aai a?iiaoiu?euei?noue, o?a?ic, aocie iaee 34,0% ae?oae ?c aeicaie I-131 ia UC (P<0,0001). Aiaeii/an ii?iaeueio aoiu?euei?noue UC iaee eeoa 64,9% ae?oae, ui aoei a??ia?aeii iaioei, i?ae o a?oi? ii??aiyiiy (98,3% ae?oae); (P<0,0001). Aiae?c aeaieo ai?noo e?ioioeeoa?ieo noaiiioeyoe?e na?aae ae?oae, ye? caciaee ii?ii?iaiiy UC a?ae I-131 aeaco? ia oa, ui ?nio? a??ia?aeia ??cieoey ??ai?a CD3+CD4+ ee?oei o ae?oae ?c aeicaie I-131 >
2,0 A? ia UC oa ae?oae ye c aeicaie I-131 < 1,0 A?, oae ? ae?oae a?oie ii??aiyiiy (oaae. 2). ??aaiue CD3+CD8+ ee?oei o ae?oae ?c aeicaie I-131 < 1,0 A? aoa a??ia?aeii aeuei, i?ae o ae?oae ?c aeicaie ?-131 ia UC > 2,0 A?. Oea ?aae?coaaeiny o a??ia?aeii i?aeaeuaia
CD3+CD4+/CD3+CD8+ ee?oeiia ni?aa?aeiioaiiy o ae?oae c aeicaie ?-131 >
2,0 A? ia UC o ii??aiyii? c ae?oueie, ye? iaee aeice I-131 iaio i?ae
2,0 A? oa ae?oueie eiio?ieueii? a?oie. Aaniethoia e?euee?noue CD3+CD8+
ee?oei o ae?oae ?c aeicaie ?-131 ia UC > 2,0 A? (0,58 + 0,05 x 10 /L)
aoea a??ia?aeii ieae/ith, i?ae o ae?oae ?c aeicaie ?-131 ia UC < 1,0 A? (0,91 + 0,08 x 10 /L; P < 0,05) oa eiio?ieth (0,84 + 0,06 x 10 /L; P<0,005). E?euee?noue CD3+, CD3+CD4+ oa CD3-/CD16+,56+ ee?oei ia a?ae??ciyeany a?ae eiio?ieth, a e?euee?noue CD19+ B-ee?oei aoea a??ia?aeii ieae/ith iacaeaaeii a?ae aeice ii?ii?iaiiy UC a?ae I-131. Oaaeeoey 2. A?aenioeiaee ai?no aieiaieo e?ioioeeoa?ieo noaiiioeyoe?e ia?eoa?e/ii? e?ia? o ae?oae, ye? caciaee ii?ii?iaiiy UC, (M+m). E?ioioeeoa?i? noaiiioeyoe?? ca Ae?oe a?oie ii?eaiyiiy Ae?oe ?c ?IAe ueoiaeaeii? caeice iiaa?oiaaeie < 1,0 A? 1,0-2,0 A? > 2,0 A?

aioeaaiaie (n=45) (n=49) (n=38) (n=19)

CD3+ T-ee?oeie 66,9+0,8 67,0+1,1 65,4+1,0 67,9+1,2

CD3+CD4+ ee?oeie 35,7+0.7 36,1+1.0 37,2+1.1 40,6+0,9*, #

ND3+CD8+ ee?oeie 25,4+0,8 26,4+0,7 25,0+0,8 22,3+0,9*

CD3+CD4+/ CD3+CD8+ ni?aa?aeiioaiiy 1,5+0,1 1,4+0,06 1,6+0,1 1,9+0,1@, #

CD19+ B-ee?oeie 15,8+0,7 13,2+0,6# 12,5+0,9# 13,2+0,7

CD3-CD16+,CD56+ IE 11,4+0,7 13,3+0,9 14,7+1,1# 12,1+0,9

I?ei?oee:

1.* — P < 0,05 o ii??aiyii? c ae?oueie, ye? iaee aeice I-131 ia UC iaio, i?ae 1,0 A?; 2.# - P < 0,01 o ii??aiyii? c eiio?ieai; 3.@ - P < 0,05 o ii??aiyii? c ae?oueie, ye? iaee aeice I-131 ia UC iaio, i?ae 1,0 A? aai 1,0-2,0 A?. Oaeei /eiii, aeai?, ye? aoee io?eiai? i?ioyaii anueiai aeine?aeaeaiiy, aeacothoue ia I-131 aeicicaeaaeio oaiaeaioe?th aei a?iioe?ai?aeecio na?aae ae?oae, ye? iino?aaeaeaee aiane?aeie ii?ii?iaiiy UC o 1986 ?ioe?. E??i oiai, aiae?c aeaieo aeine?aeaeaiiy na?ae/eoue i?i iayai?noue I-131 aeicicaeaaeieo oe?ai?aeieo aooi?ioiieo ?aaeoe?e. Oeth aeoieo i?aeoaa?aeo? oaeiae: 1) a??ia?aeia iiceoeaia ei??aeyoe?eia caeaaei?noue i?ae ??aiyie OAA (r= 0,350, P < 0,012), TMA (r= 0,688, P < 0,040) oa aeicaie I-131 ia UC; 2) iiceoeaia ei?aeyoe?y i?ae aeicaie ?aae?ieiaeo ia UC oa ye ??aiyie CD3+CD4+ ee?oei (r=0,163; P<0,02), oae ? CD3+CD4+/CD3+CD8+ ee?oeiiei ni?aa?aeiioaiiyi (r=0,266; P<0,002) (?en. 2); 3) iaaaoeaia ei?aeyoe?eia caeaaei?noue i?ae aeicaie ?aae?ieiaeo ia UC oa ye a?aenioeiaeie ??aiyie (r= -0,182; P<0,01), oae ? aaniethoiith e?euee?noth CD3+CD8+ ee?oei (r= -0,174; P<0,015). Aea/aiiy ie?aieo iaoai?ci?a a?aeiia?ae? ?ioiii? nenoaie ia ii?ii?iaiiy UC a?ae I-131 aeyaeei iciaee aeoeaaoe?? ?ioiii? cenoaie o aeaeyae? a??ia?aeiiai cieaeaiiy aeni?an?? CD62L iieaeoee ia iiaa?oi? CD4+ ee?oei (Getenby P.A., 1982; Kansas G.S., 1985) i?e ??ai? ?IAe ia UC a?ae I-131 o ae?oae a?eueo i?ae 0,7 A?. Aiaeii/an aeey ae?oae, ye? caciaee aino?iai ii?ii?iaiiy UC a?ae I-131 oa?aeoa?iei aoei oaeiae cia/ia cieaeaiiy ??ai?a aeni?an?? CD45RA+ aioeaaio ia iiaa?oi? CD4+ ee?oei oiaoi ee?oei, ye? ni?iiiaei? ?iaeoeoaaoe i?eai?/aiiy ?ioiii? a?aeiia?ae?. I?e oeueiio ??aaiue CD5+ B-ee?oei iiceoeaii ei?aethaaa ?c ??aiai OIA (r= 0,629; P<0,05), ui oe?eeii ?iia??ii na?ae/eoue i?i i?enooi?noue aooi?ioiiiai eiiiiiaioo o ooieoe?iioaaii? B-ee?oeiii? eaiee ?ioi?oaoo (Hardy R.R., 1987; Iwatani Y., 1989). A?aeiii oaeiae, ui i?e aooi?ioii?e iaoieia?? UC ?nio? B-ee?oeiia ?io?eueo?aoe?y oeueiai i?aaio oa ?io?aoe?ai?aei? B-Eo i?iaeoeothoue iaoiaaii? aioeo?ea (Song Yoa-Hua, 1996). Oe?eeii ?iia??ii, ui cieaeaiiy ??aiy CD19+ ee?oei ia?eoa?e/ii? e?ia? iacaeaaeii a?ae aeice I-131 ia UC iiaea na?ae/eoe i?i naeaeoeaio i?a?aoe?th oeeo ee?oei aei UC. Oae? aeai?, ia iaoo aeoieo, na?ae/aoue i?i aieea ii?ii?iaiiy a?ae ?aae?ieiaeo ia noai ye ?ioiii?, oae ? a?iio?ci-oe?ai?aeii? nenoaie ae?oae, ye? i?iaeeaathoue ia caa?oaeaieo oa?eoi??yo. ?ai?oa aoei aeiaaaeaii i?i aieea ?aae?aoe?eiiai ii?ii?iaiiy oa niiaoe/ii? iaoieia?? ia ai?no CD3+HLA-DR+ ee?oei na?aae e?ea?aeaoi??a aaa??? ia *AAN (*oiae A.A., Aaceea Ae.A., 1996; *oiae A.A., 1998). Aiaeii/an aiae?c iniaeeainoae ?ioii-ai?iiiaeueiiai noaoono na?iiiceoeaieo oa na?iiaaaoeaieo ae?oae aeaco? ia oa, ui i?enooi?noue OAA/TMA o ae?oae ?c aeicaie I-131 ia UC iia'ycaia ?c a??ia?aeiei i?aeaeuaiiyi aeni?an?? iieaeoee i?ciuei? aeoeaaoe?? (HLA-DR) ia CD3+ O-ee?oeiao, iayai?noth aeiaaee?a a?ii- aai a?ia?oe?aico, a oaeiae ?c ca?eueoaiiyi ii?ooaiue aoino?oeoo?e ia?aio?ie UC o aeaeyae? a?ii- aai a?ia?aoiu?eueiino? ?c ae?eyieaie o?a?ico. Oaeee noai ?ioiii?, a?iio?ci-oe?ai?aeii? nenoaie oa iniaeeaino? aoiii?ooaiue UC ? oa?aeoa?ieie aeey aooi?ioiiiai oe?ai?aeeoo oa oai?iae A?aeana (Pinchera A., 1980; Ishikawa N, 1987; Marcocci C., 1991) ?, ia iaoo aeoieo, na?ae/aoue i?i iiaeeeao ?aae?caoe?th aieeao ?aae?ieiaeo ia ooieoe?th a?iio?ci-oe?ai?aeii? nenoaie oa ?iaeoeoaaiiy aooi?ioiieo ii?ooaiue UC o ae?oae, ye? iino?eii i?iaeeaathoue ia oa?eoi??yo, eiioai?iiaaieo ?aae?iioee?aeaie. AENIIAEE 1. O ae?oae, ye? /anoi oai??thoue ia ?ani??aoi?i? caoai?thaaiiy (Ae*O) oa i?iaeeaathoue ia oa?eoi??yo, ui caciaee ?aae?iaeoeaiiai caa?oaeiaiiy aiane?aeie *i?iiaeeuenueei? eaoano?ioe, a??ia?aeii cieaeai a?aenioeiaee ??aaiue ye CD3+, oae ? CD3+CD4+ T-ee?oei oa ca?eueoai a?aenioie ae?oae ?c iecueeei ??aiai CD3+ O-ee?oei ia?eoa?e/ii? e?ia? (17,2% i?ioe 1,5% Ae*O a?oie ii??aiyiiy, P < 0,001). 2. Ca?eueoaiiy NNAAAe ii?ii?ithaaiiy a?ae Cs-137(134) oa Sr-90 anioe?eiaaii o Ae*O ?c cieaeaiiyi ??aiy CD3+CD4+ T-ee?oei oaeia??a/?iaeoeoi??a ia?eoa?e/ii? e?ia? oa iciaeaie caaaeueiiai aeecaaeaioaoe?eiiai neiae?iio. 3. O ae?oae, ye? caciaee aino?iai ii?ii?iaiiy UC a?ae ?aae?ieiaeo, niinoa??aa?oueny aeicicaeaaeia cieaeaiiy ye a?aenioeiaeo ??ai?a, oae ? aaniethoii? e?eueeino? CD3+CD8+ O-ee?oei oeeoioienee?a/noi?ani??a, a oaeiae aeicicaeaaeia i?aeaeuaiiy ye a?aenioeiaeo ??ai?a CD3+CD4+ T-ee?oei, oae ? CD3+CD4+/CD3+CD8+ ee?oeiiiai ni?aa?aeiioaiiy. 4. ?nio? iiceoeaia caeaaei?noue i?ae ??aiai CD5+ B-Eo oa aioeo?eaie aei i?e?iniiaeueiiai aioeaaio UC na?aae ae?oae, ye? caciaee ii?ii?iaiiy UC, ui i?aeoaa?aeaeo? iayai?noue ye aooi?ioiieo ?aaeoe?e, oae ? aooi?ioiii? iaoieia?? o oeeo ae?oae oa i?aee?oe?a. 5. Cieaeaiiy aeni?an?? iieaeoee CD62L oa i?aeaeuaiiy aeni?an?? iieaeoee CD45RA ia iiaa?oi? CD4+ ee?oei o ae?oae c aeicith ii?ii?iaiiy UC a?ae ?aae?ieiaeo i?iiaae 0,7 A? aeaco?, ui oeae ??aaiue ii?ii?iaiiy ? ii?iaiaei, uiaei aeoeaaoe?? ee?oeiii? eaiee ?ioiii? nenoaie. 6. Ae?oe, ye? caciaee aieeao ii?ii?iaiiy UC a?ae I-131, iathoue ci?ie o ooieoe?iioaaii? a?iio?ci-oe?ai?aeii? nenoaie o aeaeyae? i?aeaeuaieo ne?iaaoeiaeo eiioeaio?aoe?e OOA oa aeicianioe?eiaaii? noeeueiino? aei a?iioe?ai?aeecio. 7. Na?aae ae?oae, ye? caciaee ii?ii?iaiiy UC a?ae I-131, iayai?noue oee?eoethth/eo aooiaioeo?e aei UC aeyaey?oueny o 4-5 ?ac?a /ano?oa, i?ae o a?oi? ii??aiyiiy. E??i oiai, ?nio? I-131 aeicicaeaaeia i?aeaeuaiiy ??ai?a oeeo aooiaioeo?e. 8. Iayai?noue ne?iaaoeiaeo aooiaioeo?e aei UC o ae?oae, ye? caciaee ii?ii?iaiiy UC a?ae I-131, noi?iaiaeaeo?oueny cia/ieie ii?ooaiiyie aoino?oeoo?e UC. Aiaeii/an aeey na?iiaaaoeaieo ca aooiaioeo?eaie aei UC ae?oae oa?aeoa?ia iayai?noue aoce?a UC, a aeey na?iiiceoeaieo - a?ia?aoiaaii?noue ia?aio?ie c ae?eyieaie o?a?ico. IAOEIAI-I?AEOE*I? ?AEIIAIAeAOe?? 1. C iaoith aeyaeaiiy, ye iiaeeeai ?ai?oa, ?ioiiaeao?oeeoieo noai?a oa oe?ai?aeii? iaoieia?? o ae?oae, ye? iaoeathoue ia caa?oaeiaieo ?aae?iioee?aeaie oa?eoi??yo, ia??iaee/i? ee?i?/i? iaeyaee iiaeii? aeeth/aoe ?ioiieia?/ia aeine?aeaeaiiy e?ioioeeoa?ieo noaiiioeyoe?e ia?eoa?e/ii? e?ia? ia iaiueo, i?ae iaeei ?ac ia ??e. 2. A?aeoeeaiiy a ?ioii?e nenoai? ae?oae, ye? caciaee ?aae?aoe?eiiai aieeao aiane?aeie eaoano?ioe ia *AAN, iiaeooue aooe ??ciini?yiiaaieie oa caeaaeaoe a?ae aeice ii?ii?iaiiy. Oiio ?aeiiaiaeo?oueny aeei?enoaiiy ??ai?a CD3+CD4+ O-ee?oei oa CD3+CD4+/CD3+CD8+ ee?oeiiiai ni?aa?aeiioaiiy ye a?ieia?/ieo ia?ea??a ?ioiii? a?aeiia?ae? ia ii?ii?iaiiy oa iayai?noue ?ioiiaeao?oeeoiiai noaio aai aooi?ioiii? oe?ai?aeii? iaoieia??. 3. Ae?oe, o yeeo aeyaeai? iaoieia?/i? ci?ie a UC, iio?aaothoue aea?/? ia ??e oeueo?acaoeiaiai aeine?aeaeaiiy UC, ianoaaeaiiy ooieoe?? a?iio?ca?ii-oe?ai?aeii? nenoaie oa iiaeeaeaiiai ?ioiieia?/iiai ianoaaeaiiy c iiaeaeueoith ei?aeoe??th ?o noaio caei?ia'y. 4. Aeey aeyaeaiiy oeeo oa ?ioeo a?aeoeeaiue o ooie?iioaaii? ?ioiii? nenoaie, a oaeiae ?o ei?aeoe?? iiaeeaeaiee iaeyae ae?oae oa i?aee?oe?a, ye? iaoeathoue ia caa?oaeaiieo ?aae?iioee?aeaie oa?eoi??yo, iiaeiai iaoe ?aae?iiao?e/iee noi?ia?ae oa aeeth/aoe ?ioiieia?/iee, oeueo?acaoeiaee ? ai?iiiaeueiee ne?ei?ia. NIENIE IAOEIAEO I?AOeUe, IIOAE?EIAAIEO CA OAIITH AeENA?OAOe??: 1. Chernyshov V.P., Vykhovanets E.V., Slukvin I.I., Antipkin Y.G., Vasyuk A.N., Strauss K.W. Analysis of blood lymphocyte subsets in children living on territory that received high amount of fallout from Chernobyl accident // Clinical Immunology and Immunopathology.- 1997.- Vol. 84.- N.2.- P. 122-128. 2. Vykhovanets E.V., Chernyshov V.P., Slukvin I.I., Antipkin Y.G., Vasyuk A.N., Klimenko H.F., Strauss K.W. I-131 dose-dependent thyroid autoimmune disorders in children living around Chernobyl // Clinical Immunology and Immunopathology.- 1997.- Vol. 84.- N.3.- P. 251-259. 3. Aioeie?i TH.A., Iiaeue/aiei E.?., Ii/eiie O.A., *a?ieoia A.I., A?aanueea E.I., Aanthe A.I., Aeoiaaiaoeue ?.A. Ee?i?ei-?ioiieia?/ia oa?aeoa?enoeea aoi?eiieo ?ioiiaeao?oeeo?a ?ioaeoe?eiiai iioiaeaeaiiy o ae?oae // Iniaeeaino? ia?aa?ao aaa?oiino?, ?iae?a, noaio iiaiia?iaeaeaieo oa i?iya?a niiaoe/ii? ineoiiaa?ieia?/ii? iaoieia?? o ae?oae, ye? caciaee ?aae?aoe?eiiai aieeao aiane?aeie *i?iiaeeuenei? eaoano?ioe / I?ae ?aaeaeoe??th I.I. Eoe'yiiai?.- E.: *i?iiaeeue?ioa?oi?i.- 1997.- C. 83-94. 4. Strauss K., Chernyshov V.P., Vykhovanets E.V., Antipkin Y.G., Klimenko H.P., Vasyuk A.N., Slukvin I.I. Immune system of Chernobyl children: Development in understanding // One decade after Chernobyl: Summing up the consequences of the accident / IAEA (Austria, Vienna).- 1997.- Vol. 1.- P. 151-158. 5. *a?ieoia A.I., Auoiaaiaoe A.A., Aioeieei TH.A., Neoeaei E.E., Aanthe A.I., Eeeiaiei A.O. Aicaeaenoaea ecioiia eiaea ia ninoiyiea aeiioeca?ii-oe?aieaeiie e eiioiiie nenoai o aeaoae, i?iaeeaathueo ia oa??eoi?eyo, caa?yciaiiuo ?aaeeiioeeeaeaie // Atheeaoaiue aenia?eiaioaeueiie aeieiaee e iaaeeoeeiu.- 1998.- O. 126.- N.8.- N. 216-220. 6. Chernyshov V.P., Vykhovanets E.V., Antipkin Y.G., Vasyuk A.N., Klimenko E.F. Analysis of blood lymphocyte Late I-131 dose-dependent autoimmune thyroid disorders of children living around Chernobyl // The Immunologist.- 1998.- Suppl. 1.- P. 183. Aeoiaaiaoeue ?.A. Iniaeeaino? noaiiioeyoe?eiiai neeaaeo e?ioioeeo?a ia?eoa?e/ii? e?ia? ae?oae, ye? i?iaeeaathoue ia oa?eoi??yo ?c i?aeaeuaiei ??aiai ?aae?iioee?ae?a.- ?oeiien. Aeena?oaoe?y ia caeiaoooy iaoeiaiai nooiaiy eaiaeeaeaoa iaaee/ieo iaoe ii niaoe?aeueiino? 14.01.29.- ee?i?/ia ?ioiieia?y.- ?inoeooo ooec?ao??? ? ioeueiiiieia?? ?i. O.A. ssiianueeiai AII Oe?a?ie, Ee?a, 1998. I?aaenoaaeai? ?acoeueoaoe aeine?aeaeaiiy noaio ?ioiii? oa a?iio?ci-oe?ai?aeii? nenoai o ae?oae, ye? i?iaeeaathoue ia oa?eoi??yo, ui caciaee caa?oaeiaiiy a?ae ?aae?iioee?ae?a aiane?aeie *i?iiaeeuenueei? eaoano?ioe. Anoaiiaeaii aieea iaeeo aeic ii?ii?iaiiy ia ?ioiio nenoaio ? iayai?noue ?-131 aeicicaeaaeieo oe?ai?aeieo aooi?ioiieo ii?ooaiue. C o?aooaaiiyi iaea?aeaieo ?acoeueoao?a iaa?oioiaaia iaiao?aei?nue ?aaoey?iiai ?ioiieia?/iiai ianoaaeaiiy ae?oae, ye? iino?aaeaeaee aiane?aeie aaa??? ia *i?iiaeeuenuee?e AAN. Eeth/ia? neiaa: *i?iiaeeuenueea eaoano?ioa, e?ioioeeoa?i? noaiiioeyoe??, ueoiaeaeia caeica, ae?oe. Auoiaaiaoe A.A. Iniaaiiinoe noaiiioeyoeeiiiiai ninoaaa eeioioeeoia ia?eoa?e/aneie e?iae aeaoae, i?iaeeaathueo ia oa??eoi?eyo n iiauoaiiui o?iaiai ?aaeeiioeeeaeia.- ?oeiienue. Aeenna?oaoeey ia nieneaiea o/aiie noaiaie eaiaeeaeaoa iaaeeoeeineeo iaoe ii niaoeeaeueiinoe 14.01.29. - eeeie/aneay eiioiieiaey.- Einoeooo ooeceao?ee e ioeueiiiieiaee ei. O.A. ssiianeiai AII Oe?aeiu, Eeaa, 1998. I?aaenoaaeaiu ?acoeueoaou enneaaeiaaiey ninoiyiey eiioiiie e aeiioeci-oe?aieaeiie nenoai o aeaoae, i?iaeeaathueo ia oa??eoi?eyo, caa?yciaiiuo ?aaeeiioeeeaeaie aneaaenoaea *a?iiaueueneie eaoano?iou. Auyaeaii aeeyiea iaeuo aeic iaeo/aiey ia eiioiioth nenoaio e i?enoonoaea I-131 aeicicaaeneiuo oe?aieaeiuo aooieiioiiuo ia?ooaiee. N o/aoii iieo/aiiuo ?acoeueoaoia iainiiaaia iaiaoiaeeiinoue ?aaoey?iuo eiioiieiae/aneeo ianeaaeiaaiee aeaoae, iino?aaeaaoeo a ?acoeueoaoa aaa?ee ia *a?iiaueueneie AYN. Eeth/aaua neiaa: *a?iiaueueneay eaoano?ioa, eeioioeeoa?iua noaiiioeyoeee, ueoiaeaeiay aeaeaca, aeaoe. Vykhovanets E.V. Peculiarities of the lymphocyte subsets of peripheral blood in children living on territories with high levels of radionuclidies.- Manuscript. Thesis for competition of scientific degree of candidate of medical sciences by speciality 14.01.29. - clinical immunology.- The Institute of Tuberculosis & Pulmonology named by F.G. Yanovsky of the Academy of Medical Science of Ukraine, Kyiv, 1998. The results of study of immune and hypophisio-thyroid systems of children living on areas that contaminated by Chornobyl accident fallout are presented. The data indicated that exposure to small doses could affect the immune system. I-131 dose-dependent thyroid autoimmune disorders were also observed in children living around Chornobyl. The monitoring of immune system of these children are proposed. Key words: Chornobyl accident, lymphocyte subsets, thyroid, children.

Похожие записи